Loading...


  • anticoagulation therapy
  • The reference range for prothrombin time depends on the analytical method used, but is usually around 12-13 seconds (results should always be interpreted using the reference range from the laboratory that performed the test), and the INR in absence of anticoagulation therapy is 0.8-1.2. (wikipedia.org)
  • Unfortunately, robust and individually-tailored anticoagulation therapy protocols do not exist in most institutions, which usually utilize a "one size fits all" approach. (wikipedia.org)
  • Predictors
  • Predictors of persistence on warfarin included: African American race (vs. White) 1.53 (1.07-2.19), Hispanic ethnicity (vs. White) 1.66 (1.06-2.60), paroxysmal and persistent AF (vs. new-onset) 1.68 (1.21-2.33) and 1.91 (1.35-2.69) respectively, LVH 1.40 (1.08-1.81), and CHA 2 DS 2 -VASc risk scores ≥ 2 1.94 (1.18-3.19). (springer.com)
  • persistence
  • Cox proportional hazards models were used to estimate the relationship between covariates affecting initiation and non-persistence with warfarin treatment. (frontiersin.org)
  • clot
  • Warfarin is best suited for anticoagulation (clot formation inhibition) in areas of slowly running blood (such as in veins and the pooled blood behind artificial and natural valves) and in blood pooled in dysfunctional cardiac atria. (wikipedia.org)
  • Dosing
  • We will then develop a dosing equation for warfarin using patient, environmental and genetic factors. (clinicaltrials.gov)
  • A randomized trial of genotype-guided dosing of warfarin. (clinicaltrials.gov)
  • In addition, protein C, protein S and factor II levels will be obtained while the patient is on stable maintenance dosing of warfarin (i.e., prior to holding warfarin for the procedure), 7 days after re-starting warfarin, and 14 days after re-starting warfarin. (clinicaltrials.gov)
  • Dosing of warfarin is complicated because it is known to interact with many commonly used medications and certain foods. (wikipedia.org)
  • Inappropriate dosing of warfarin has been associated with a substantial risk of both major and minor hemorrhage. (wikipedia.org)
  • Embolism
  • Warfarin treatment can help prevent formation of future blood clots and help reduce the risk of embolism (migration of a thrombus to a spot where it blocks blood supply to a vital organ). (wikipedia.org)
  • vascular
  • Long-term low levels of vitamin K, influenced by CYP4F2 genotype, might affect bone development and vascular health in children on chronic warfarin therapy. (ovid.com)
  • This absence of consensus reflects the lack of evidence in this area and different outlooks on the objectives of such therapy (e.g., prevention of arterial emboli or reduction in vascular events). (clinicaltrials.gov)
  • protein
  • the smaller dose also avoids the development of a potential hypercoagulable state caused by precipitous decreases in levels of protein C during the first 36 hours of warfarin therapy. (nih.gov)
  • It is a gla domain protein and thus vitamin K-dependent, and its functionality is therefore impaired in warfarin therapy. (wikipedia.org)
  • oral
  • Both oral and intravenous (IV) routes are effective in reducing a raised INR due to warfarin with a similar correction of INR by 24 hrs. (transfusion.com.au)
  • enzyme
  • Warfarin is an anticoagulant that opposes the procoagulant effect of vitamin K by inhibiting the VKORC enzyme. (wikipedia.org)
  • These isoforms result in warfarin resistance (requiring higher doses) in humans and rats, because the amount and effectiveness of the VKORC enzyme has not changed, but the ability of warfarin to exert its effect (antagonize the enzyme) has changed. (wikipedia.org)
  • regimen
  • documentation in the patient's medical notes regarding commencement of warfarin, the loading dose given, the loading regimen over days 2-7 and the international normalised ratio (INR) target at discharge. (bmj.com)
  • patient
  • no documented reason why warfarin started or that verbal or written information given to patient/parents, the majority of loading doses used were documented and all of the INR results post surgery was detailed. (bmj.com)
  • Bleeding
  • Bleeding is the most common complication of warfarin therapy and elevated INR is a significant risk factor. (transfusion.com.au)
  • The rest were ineligible based on risk of bleeding because of inability to comply with monitoring to make sure warfarin was in the target range, predisposition to falls or head trauma, persistent hypertension, prior serious bleeding on anticoagulation, or other factors. (medpagetoday.com)
  • The combination of argatroban and warfarin may raise the INR to greater than 5.0 without a significant increased risk of bleeding complications. (wikipedia.org)
  • symptoms
  • PROSPER enrolled patients with prostate cancer that had progressed, based on a rising prostate-specific antigen (PSA) level despite androgen deprivation therapy (ADT), but who had no symptoms with no prior or present evidence of metastatic disease. (yahoo.com)
  • Confirm eradication of Helicobacter pylori after therapy in patients with H. pylori -associated ulcer, continued dyspeptic symptoms, mucosa-associated lymphoid tissue lymphoma, and resection of gastric cancer. (aafp.org)
  • Dutasteride and tamsulosin are on the market as combined therapy and results have shown that they improve symptoms significantly versus monotherapy. (wikipedia.org)
  • clinical
  • In patients of all ages who are started on antidepressant therapy monitor closely for clinical worsening and emergence of suicidal thoughts and behaviors. (rxlist.com)
  • Chelation therapy has a long history of use in clinical toxicology and remains in use for some very specific medical treatments, although it is administered under very careful medical supervision due to various inherent risks. (wikipedia.org)
  • patients
  • Pfizer Inc. ( PFE ) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") announced today that the Phase 3 PROSPER trial evaluating XTANDI ® (enzalutamide) plus androgen deprivation therapy (ADT) versus ADT alone in patients with non-metastatic (M0) Castration-Resistant Prostate Cancer (CRPC) met its primary endpoint of improved metastasis-free survival (MFS). (yahoo.com)
  • Therapy should be initiated at 0.125 mg in these groups and the 0.25 mg dose should be used only for exceptional patients who do not respond to a trial of the lower dose. (rxlist.com)
  • As a patient with elevated liver aminotransferases, while integrating an effective course of low-dose G-CSF may benefit some patients who do not respond to 12 months of the where can i buy accutane in nigeria breakdown of initiating therapy. (bnnpsulteng.com)
  • Patients achieving a complete response (CR) receive 2 courses of therapy beyond CR. (clinicaltrials.gov)
  • Recommended therapies for preventing PUD in these patients include misoprostol and proton pump inhibitors. (aafp.org)
  • In the 1950s, Norman Clarke, Sr. was treating workers at a battery factory for lead poisoning when he noticed that some of his patients had improved angina pectoris following chelation therapy. (wikipedia.org)
  • lead
  • Following World War II, chelation therapy was used to treat workers who had painted United States naval vessels with lead-based paints. (wikipedia.org)
  • levels
  • When administered inappropriately, there are the additional risks of hypocalcaemia (low calcium levels), neurodevelopmental disorders, and death Chelation therapy can be traced back to the early 1930s, when Ferdinand Munz, a German chemist working for I.G. Farben, first synthesized ethylenediaminetetraacetic acid (EDTA). (wikipedia.org)